2008Medical Journal of National Defending Forces in Northwest ChinaRequires access

Azithromycin-Clindamycin alternate treatment for pediatric mycoplasmal pneumonia

Sun Ya

Open publisher page 0 citations

Abstract

Objective:To investigate the effect and the safety of Azithromycin-Clindamycin alternate treatment for pediatric mycoplasmal pneumonia. Methods: 76 cases of pediatric mycoplasma pneumonia were divided into two groups: Azithromycin-Clindamycin alternate treatment group (n=30) and Azithromycin treatment group (n=46). In Azithromycin-Clindamycin alternate treatmet group, Azithromycin was given by intravenous drips in the first three days (1/d, 10 mg/kg-1·d-1), Clindamycin was given by intravenous drips in the following four days (2/d, 40 mg/kg-1·d-1), and Azithromycin was again given by intravenous drips from the eighth day to the tenth day with the same dosage. In Azithromycin treatment group, Azithromycin was given by intravenous drips for three days (1/d, 10 mg/kg-1·d-1). Results:The effect of the Azithromycin-Clindamycin alternate treatment was better than that of the Azithromycin treatment, while there was no significant difference in the adverse effect incidence between two groups. Conclusion:The effect of Azithromycin-Clindamycin alternate treatment for the pediatric mycoplasma pneumonia is better than that of Azithromycin treatment.

About this research paper

What this paper is about

Objective:To investigate the effect and the safety of Azithromycin-Clindamycin alternate treatment for pediatric mycoplasmal pneumonia. Methods: 76 cases of pediatric mycoplasma pneumonia were divided into two groups: Azithromycin-Clindamycin alternate treatment group (n=30) and Azithromycin treatment group (n=46). In Azithromycin-Clindamycin alternate treatmet group, Azithromycin was given by intravenous drips in the first three days (1/d, 10 mg/kg-1·d-1), Clindamycin was given by intravenous drips in the following four days (2/d, 40 mg/kg-1·d-1), and Azithromycin was again given by intravenous drips from the eighth day to the tenth day with the same dosage. In Azithromycin treatment group, Azithromycin was given by intravenous drips for three days (1/d, 10 mg/kg-1·d-1). Results:The effect of the Azithromycin-Clindamycin alternate treatment was better than that of the Azithromycin treatment, while there was no significant difference in the adverse effect incidence between two groups. Conclusion:The effect of Azithromycin-Clindamycin alternate treatment for the pediatric mycoplasma pneumonia is better than that of Azithromycin treatment.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To investigate the effect and the safety of Azithromycin-Clindamycin alternate treatment for pediatric mycoplasmal pneumonia. Methods: 76 cases of pediatric mycoplasma pneumonia were divided into two groups: Azithromycin-Clindamycin alternate treatment group (n=30) and Azithromycin treatment group (n=46). In Azithromycin-Clindamycin alternate treatmet group, Azithromycin was given by intravenous drips in the first three days (1/d, 10 mg/kg-1·d-1), Clindamycin was given by intravenous drips in the following four days (2/d, 40 mg/kg-1·d-1), and Azithromycin was again given by intravenous drips from the eighth day to the tenth day with the same dosage. In Azithromycin treatment group, Azithromycin was given by intravenous drips for three days (1/d, 10 mg/kg-1·d-1). Results:The effect of the Azithromycin-Clindamycin alternate treatment was better than that of the Azithromycin treatment, while there was no significant difference in the adverse effect incidence between two groups. Conclusion:The effect of Azithromycin-Clindamycin alternate treatment for the pediatric mycoplasma pneumonia is better than that of Azithromycin treatment.

Key concepts: Azithromycin, Clindamycin, Medicine, Mycoplasma pneumonia, Pneumonia, Incidence (geometry), Internal medicine, Antibiotics

Related papers

Back to paper searchBrowse research topicsOriginal source
Azithromycin-Clindamycin alternate treatment for pediatric mycoplasmal pneumonia — Research Paper | ScholarLens